Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
ClearPoint Neuro, Inc. director Timothy T. Richards exercised stock options and had shares withheld to cover taxes. He exercised options for 500 shares of Common Stock at $10.00 per share and 376 shares were disposed of at $13.30 per share for tax-withholding. Following these transactions, he directly owned 87,322 Common Stock shares, and the exercised option grant was fully used.
ClearPoint Neuro director Timothy T. Richards sold 5,415 shares of Common Stock. The open-market sale on June 1, 2026 was executed at a weighted average price of $12.17 per share, with individual trades ranging from $12.04 to $12.47 per share.
According to the filing, the sale was made to cover the tax liability associated with the vesting of 12,417 restricted stock units on May 19, 2026. After this transaction, Richards directly holds 87,198 shares of ClearPoint Neuro common stock.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale of 5,145 shares of Common Stock. The filing lists an aggregate value of $62,611.56 and reports 29,989,563 shares outstanding as of 06/01/2026 as context. The shares arose from restricted stock vesting under a registered plan on 05/20/2026.
FALLON LYNNETTE C reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Lynnette C. Fallon received a grant of 12,820 restricted stock units of common stock. Each unit represents a right to receive one CLPT share. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the company’s 2027 annual meeting.
LIAU LINDA M. reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. director Linda M. Liau reported an equity award of restricted stock units. She received 12,820 restricted stock units, each representing a contingent right to receive one share of ClearPoint Neuro common stock. The units were granted at a price of $0.00 per unit.
The restricted stock units vest on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual meeting of stockholders. Following this grant, she directly holds 12,820 restricted stock units corresponding to 12,820 shares of common stock.
ClearPoint Neuro director Matthew B. Klein reported mixed equity activity. On May 21, 2026, he completed an open-market sale of 16,000 shares of common stock at a weighted average price of $11.59 per share and held 46,935 shares directly afterward. The sale prices ranged from $11.57 to $11.65.
On the same date, he received a grant of 12,820 restricted stock units (RSUs), each representing a contingent right to one share of ClearPoint Neuro common stock. These RSUs vest on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual meeting of stockholders.
Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. director Timothy T. Richards received a grant of 12,820 restricted stock units. Each unit represents a right to receive one share of CLPT common stock and will vest on the earlier of the first anniversary of the grant date or the day immediately before the 2027 annual meeting of stockholders.